Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole.
Recurrent/metastatic endometrial adenocarcinoma that is not amenable to cure with local or regional therapy and/or chemotherapy represents a discouraging clinical entity for the clinician. We report the case of 58-year-old woman with recurrent endometrial carcinoma that was resistant to chemotherapy that was treated successfully with the aromatase inhibitor anastrozole.
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology Yale University School of Medicine, New Haven, CT 06520-8063, USA.
Stefania
S
Bellone
Hemendrah R
HR
Shah
Jesse K
JK
McKenney
Pamela J B
PJ
Stone
Alessandro D
AD
Santin
D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology / Q000556:secondary; D000077384:Anastrozole; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D016889:Endometrial Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000556:secondary; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging / Q000188:drug therapy*; D009570:Nitriles / Q000627:therapeutic use*; D011960:Receptors, Estrogen / Q000378:metabolism; D014057:Tomography, X-Ray Computed; D014230:Triazoles / Q000627:therapeutic use*
D047072:Aromatase Inhibitors; D009570:Nitriles; D011960:Receptors, Estrogen; D014230:Triazoles; D000077384:Anastrozole